Physician profile
Caitlyn E Mcbride
NPI 1316602006
$1,961.56
in general payments reported to CMS, 2019-2025
17 companies · $687 in 2025
The $687 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $202 · 2023: $534 · 2024: $538 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $418.54 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $339.58 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.57 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $200.20 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $191.43 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $150.38 | 2023-2025 | Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $81.19 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $71.77 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $59.91 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $55.08 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Seqirus USA INC | $45.96 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Sanofi Pasteur INC. | $41.07 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $21.51 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $18.12 | 2023 | Gvoke Hypopen |
| Abbvie INC. | $15.04 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $14.71 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $14.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlyn Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.